With India facing a major obesity crisis (hundreds of millions affected), Emcure is positioning Poviztra to compete with new low-cost generics hitting the market.
CEO Satish Mehta says they're The revised pricing of Poviztra is a step toward making scientifically validated weight-management therapies more accessible and affordable to a wider patient base.
and hopes this price drop helps more people get effective treatment when it matters most.